Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Jun 3, 2024

Press releases

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Evaxion reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company’s AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 28, 2024

Press releases

Evaxion Announces Business Update and First Quarter 2024 Financial Results

Evaxion provides business update and announces first quarter 2024 financial results.

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 23, 2024

Press releases

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024.

Evaxion Receives Nasdaq Notification

May 10, 2024

Press releases

Evaxion Receives Nasdaq Notification

Evaxion announces that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders’ equity requirement.

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 17, 2024

Press releases

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Apr 2, 2024

Press releases

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 27, 2024

Press releases

Evaxion Announces Business Update and Full Year 2023 Financial Results

Evaxion today provides a business update and announces full year 2023 financial results.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Mar 19, 2024

Press releases

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform.

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 29, 2024

Press releases

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST.